A clinical stage company is going to study the effectiveness of their investigational antiviral against multiple respiratory viruses.
Image credit: Towfiqu Barbhuiya, unsplash
Shelton, Connecticut-based NanoViricides, a development stage company that focuses on broad-spectrum antiviral nano therapies, announced today they have started planning for phase 2 clinical studies for their investigational antiviral, NV-387, as a potential treatment for RSV, influenza, and COVID-19.
What You Need to Know
NanoViricides, a development stage company, is planning phase 2 clinical studies for their antiviral drug NV-387. This drug has shown activity against respiratory viruses like RSV, influenza, and COVID-19 in animal models, positioning it as a potential treatment for multiple respiratory infections.
NV-387 has demonstrated strong activity against various viruses, including RSV, Influenza, Coronaviruses, and orthoPoxviruses (such as mpox). The drug’s biomimicry mechanism acts as a decoy to the virus, reducing the likelihood of viral escape and providing significant lung protection during respiratory infections.
The company completed phase 1 clinical trials in collaboration with Karveer Meditech Pvt Ltd in India, reporting no adverse events.
According to NanoViricides, NV-387 has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications.
There are several respiratory viruses that continue to cause seasonal outbreaks with Influenza, RSV, and COVID-19 annually. The potential for avian influenza emerging as well as increases in COVID-19 incidence rates can create public health challenges, and can spread further into mammals and mutate into new variants.
NV-387 is being studied to see its effectiveness against many of these viruses. The company is eyeing other indications even orthoPoxviruses, such as mpox, in relevant animal models.
NV-387 ihas shown strong activity against all of the aforementioned viruses, namely, RSV, Influenza, coronaviruses. The company reports that NV-387 treatment also protected lungs from damage, which is very important for respiratory viral infections.
According to the companyâs statement, NV-387 is unlikely to escape viruses, because of its biomimicry, presenting itself to the virus as a decoy of the host cell.
The company completed phase 1 clinical trials with NV-387 and they reported no adverse events. This trial was conducted by the drug sponsor, Karveer Meditech Pvt Ltd, their licensee and collaborator in India.
In their statement, NanoViricides plans to pursue the fastest regulatory path feasible towards regulatory approvals in different countries including the United States. plan to license or co-develop our various drug candidates against multiple viral diseases to other Pharma Companies. In addition, NanoViricides plans to seek non-dilutive funding for the development of drugs that are of interest for biodefense.
